nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—PTGS1—Etoposide—urinary bladder cancer	0.0594	0.177	CbGbCtD
Irbesartan—CYP3A4—Thiotepa—urinary bladder cancer	0.0513	0.153	CbGbCtD
Irbesartan—CYP2C8—Fluorouracil—urinary bladder cancer	0.0411	0.122	CbGbCtD
Irbesartan—CYP2C8—Etoposide—urinary bladder cancer	0.0343	0.102	CbGbCtD
Irbesartan—CYP1A2—Fluorouracil—urinary bladder cancer	0.0318	0.0947	CbGbCtD
Irbesartan—CYP2C9—Fluorouracil—urinary bladder cancer	0.0287	0.0854	CbGbCtD
Irbesartan—CYP1A2—Etoposide—urinary bladder cancer	0.0266	0.0791	CbGbCtD
Irbesartan—CYP2C9—Cisplatin—urinary bladder cancer	0.0244	0.0725	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—urinary bladder cancer	0.0149	0.0444	CbGbCtD
Irbesartan—CYP3A4—Etoposide—urinary bladder cancer	0.0139	0.0414	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—urinary bladder cancer	0.00949	0.0283	CbGbCtD
Irbesartan—EDNRA—prostate gland—urinary bladder cancer	0.00585	0.0542	CbGeAlD
Irbesartan—CYP1A2—urine—urinary bladder cancer	0.00568	0.0526	CbGeAlD
Irbesartan—CYP2C9—urine—urinary bladder cancer	0.0054	0.0499	CbGeAlD
Irbesartan—JUN—prostate gland—urinary bladder cancer	0.00534	0.0494	CbGeAlD
Irbesartan—EDNRA—seminal vesicle—urinary bladder cancer	0.00495	0.0458	CbGeAlD
Irbesartan—JUN—seminal vesicle—urinary bladder cancer	0.00452	0.0418	CbGeAlD
Irbesartan—CYP3A4—urine—urinary bladder cancer	0.00411	0.0381	CbGeAlD
Irbesartan—CYP2D6—urine—urinary bladder cancer	0.00405	0.0375	CbGeAlD
Irbesartan—AGTR1—prostate gland—urinary bladder cancer	0.00402	0.0372	CbGeAlD
Irbesartan—JUN—epithelium—urinary bladder cancer	0.00393	0.0363	CbGeAlD
Irbesartan—EDNRA—urethra—urinary bladder cancer	0.00392	0.0363	CbGeAlD
Irbesartan—JUN—smooth muscle tissue—urinary bladder cancer	0.00378	0.035	CbGeAlD
Irbesartan—JUN—renal system—urinary bladder cancer	0.00364	0.0337	CbGeAlD
Irbesartan—Losartan—UGT2B7—urinary bladder cancer	0.00364	1	CrCbGaD
Irbesartan—JUN—urethra—urinary bladder cancer	0.00358	0.0331	CbGeAlD
Irbesartan—AGTR1—epithelium—urinary bladder cancer	0.00296	0.0274	CbGeAlD
Irbesartan—JUN—female reproductive system—urinary bladder cancer	0.00292	0.027	CbGeAlD
Irbesartan—EDNRA—vagina—urinary bladder cancer	0.00289	0.0268	CbGeAlD
Irbesartan—AGTR1—smooth muscle tissue—urinary bladder cancer	0.00285	0.0264	CbGeAlD
Irbesartan—AGTR1—renal system—urinary bladder cancer	0.00274	0.0254	CbGeAlD
Irbesartan—JUN—vagina—urinary bladder cancer	0.00264	0.0244	CbGeAlD
Irbesartan—AGTR1—female reproductive system—urinary bladder cancer	0.0022	0.0203	CbGeAlD
Irbesartan—AGTR1—vagina—urinary bladder cancer	0.00199	0.0184	CbGeAlD
Irbesartan—EDNRA—lymph node—urinary bladder cancer	0.00187	0.0173	CbGeAlD
Irbesartan—PTGS1—prostate gland—urinary bladder cancer	0.00177	0.0164	CbGeAlD
Irbesartan—JUN—lymph node—urinary bladder cancer	0.00171	0.0158	CbGeAlD
Irbesartan—PTGS1—seminal vesicle—urinary bladder cancer	0.0015	0.0138	CbGeAlD
Irbesartan—CYP2C8—renal system—urinary bladder cancer	0.00149	0.0138	CbGeAlD
Irbesartan—CYP1A2—renal system—urinary bladder cancer	0.00139	0.0129	CbGeAlD
Irbesartan—PTGS1—epithelium—urinary bladder cancer	0.0013	0.012	CbGeAlD
Irbesartan—AGTR1—lymph node—urinary bladder cancer	0.00128	0.0119	CbGeAlD
Irbesartan—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00125	0.0116	CbGeAlD
Irbesartan—PTGS1—renal system—urinary bladder cancer	0.00121	0.0112	CbGeAlD
Irbesartan—CYP2C8—female reproductive system—urinary bladder cancer	0.00119	0.011	CbGeAlD
Irbesartan—CYP2C8—vagina—urinary bladder cancer	0.00108	0.00997	CbGeAlD
Irbesartan—CYP2C9—female reproductive system—urinary bladder cancer	0.00106	0.00979	CbGeAlD
Irbesartan—CYP3A4—renal system—urinary bladder cancer	0.00101	0.00932	CbGeAlD
Irbesartan—CYP2D6—renal system—urinary bladder cancer	0.000991	0.00917	CbGeAlD
Irbesartan—PTGS1—female reproductive system—urinary bladder cancer	0.000965	0.00894	CbGeAlD
Irbesartan—PTGS1—vagina—urinary bladder cancer	0.000873	0.00808	CbGeAlD
Irbesartan—CYP3A4—female reproductive system—urinary bladder cancer	0.000806	0.00746	CbGeAlD
Irbesartan—CYP2D6—female reproductive system—urinary bladder cancer	0.000793	0.00734	CbGeAlD
Irbesartan—PTGS1—lymph node—urinary bladder cancer	0.000565	0.00523	CbGeAlD
Irbesartan—Bradycardia—Epirubicin—urinary bladder cancer	0.000197	0.000692	CcSEcCtD
Irbesartan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000197	0.00069	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—urinary bladder cancer	0.000196	0.000689	CcSEcCtD
Irbesartan—Urticaria—Etoposide—urinary bladder cancer	0.000195	0.000684	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—urinary bladder cancer	0.000195	0.000683	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—urinary bladder cancer	0.000194	0.000681	CcSEcCtD
Irbesartan—Abdominal pain—Etoposide—urinary bladder cancer	0.000194	0.000681	CcSEcCtD
Irbesartan—Body temperature increased—Etoposide—urinary bladder cancer	0.000194	0.000681	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000194	0.000681	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000194	0.000681	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—urinary bladder cancer	0.000194	0.00068	CcSEcCtD
Irbesartan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000194	0.000679	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—urinary bladder cancer	0.000193	0.000677	CcSEcCtD
Irbesartan—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000193	0.000676	CcSEcCtD
Irbesartan—Asthenia—Cisplatin—urinary bladder cancer	0.000192	0.000675	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—urinary bladder cancer	0.000192	0.000674	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000192	0.000674	CcSEcCtD
Irbesartan—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000191	0.000671	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000191	0.000669	CcSEcCtD
Irbesartan—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000191	0.000668	CcSEcCtD
Irbesartan—Urethral disorder—Epirubicin—urinary bladder cancer	0.00019	0.000666	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000189	0.000662	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—urinary bladder cancer	0.000189	0.000661	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—urinary bladder cancer	0.000188	0.000659	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—urinary bladder cancer	0.000187	0.000656	CcSEcCtD
Irbesartan—Dizziness—Fluorouracil—urinary bladder cancer	0.000187	0.000656	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—urinary bladder cancer	0.000187	0.000655	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000187	0.000654	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000187	0.000654	CcSEcCtD
Irbesartan—Chills—Methotrexate—urinary bladder cancer	0.000186	0.000652	CcSEcCtD
Irbesartan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000184	0.000643	CcSEcCtD
Irbesartan—Vomiting—Gemcitabine—urinary bladder cancer	0.000183	0.000641	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—urinary bladder cancer	0.000183	0.00064	CcSEcCtD
Irbesartan—Rash—Gemcitabine—urinary bladder cancer	0.000181	0.000636	CcSEcCtD
Irbesartan—Dermatitis—Gemcitabine—urinary bladder cancer	0.000181	0.000635	CcSEcCtD
Irbesartan—Hypersensitivity—Etoposide—urinary bladder cancer	0.000181	0.000635	CcSEcCtD
Irbesartan—Tinnitus—Epirubicin—urinary bladder cancer	0.000181	0.000634	CcSEcCtD
Irbesartan—Erythema—Methotrexate—urinary bladder cancer	0.00018	0.000632	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—urinary bladder cancer	0.00018	0.000632	CcSEcCtD
Irbesartan—Headache—Gemcitabine—urinary bladder cancer	0.00018	0.000632	CcSEcCtD
Irbesartan—Flushing—Epirubicin—urinary bladder cancer	0.00018	0.000631	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00018	0.000631	CcSEcCtD
Irbesartan—Vomiting—Fluorouracil—urinary bladder cancer	0.00018	0.000631	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—urinary bladder cancer	0.00018	0.00063	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—urinary bladder cancer	0.000179	0.000629	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000179	0.000626	CcSEcCtD
Irbesartan—Rash—Fluorouracil—urinary bladder cancer	0.000178	0.000625	CcSEcCtD
Irbesartan—Dermatitis—Fluorouracil—urinary bladder cancer	0.000178	0.000625	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000178	0.000624	CcSEcCtD
Irbesartan—Headache—Fluorouracil—urinary bladder cancer	0.000177	0.000621	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000177	0.000621	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000177	0.000619	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—urinary bladder cancer	0.000177	0.000619	CcSEcCtD
Irbesartan—Asthenia—Etoposide—urinary bladder cancer	0.000176	0.000618	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000176	0.000618	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—urinary bladder cancer	0.000176	0.000617	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000176	0.000616	CcSEcCtD
Irbesartan—Immune system disorder—Epirubicin—urinary bladder cancer	0.000175	0.000614	CcSEcCtD
Irbesartan—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000175	0.000612	CcSEcCtD
Irbesartan—Chills—Epirubicin—urinary bladder cancer	0.000174	0.00061	CcSEcCtD
Irbesartan—Pruritus—Etoposide—urinary bladder cancer	0.000174	0.000609	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—urinary bladder cancer	0.000173	0.000607	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—urinary bladder cancer	0.000173	0.000606	CcSEcCtD
Irbesartan—Nausea—Gemcitabine—urinary bladder cancer	0.000171	0.000599	CcSEcCtD
Irbesartan—Vomiting—Cisplatin—urinary bladder cancer	0.000171	0.000598	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—urinary bladder cancer	0.00017	0.000596	CcSEcCtD
Irbesartan—Rash—Cisplatin—urinary bladder cancer	0.000169	0.000593	CcSEcCtD
Irbesartan—Dermatitis—Cisplatin—urinary bladder cancer	0.000169	0.000592	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—urinary bladder cancer	0.000169	0.000592	CcSEcCtD
Irbesartan—Erythema—Epirubicin—urinary bladder cancer	0.000169	0.000592	CcSEcCtD
Irbesartan—Diarrhoea—Etoposide—urinary bladder cancer	0.000168	0.000589	CcSEcCtD
Irbesartan—Nausea—Fluorouracil—urinary bladder cancer	0.000168	0.000589	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000167	0.000586	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—urinary bladder cancer	0.000167	0.000586	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—urinary bladder cancer	0.000167	0.000584	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—urinary bladder cancer	0.000167	0.000584	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000167	0.000584	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—urinary bladder cancer	0.000166	0.000583	CcSEcCtD
Irbesartan—Tension—Epirubicin—urinary bladder cancer	0.000166	0.00058	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—urinary bladder cancer	0.000165	0.000579	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—urinary bladder cancer	0.000164	0.000575	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—urinary bladder cancer	0.000163	0.00057	CcSEcCtD
Irbesartan—Malaise—Methotrexate—urinary bladder cancer	0.000163	0.00057	CcSEcCtD
Irbesartan—Dizziness—Etoposide—urinary bladder cancer	0.000163	0.00057	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—urinary bladder cancer	0.000162	0.000569	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000162	0.000568	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—urinary bladder cancer	0.000162	0.000568	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000162	0.000567	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—urinary bladder cancer	0.000161	0.000566	CcSEcCtD
Irbesartan—Chills—Doxorubicin—urinary bladder cancer	0.000161	0.000564	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00016	0.000562	CcSEcCtD
Irbesartan—Nausea—Cisplatin—urinary bladder cancer	0.000159	0.000558	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—urinary bladder cancer	0.000159	0.000557	CcSEcCtD
Irbesartan—Cough—Methotrexate—urinary bladder cancer	0.000157	0.000552	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000157	0.000549	CcSEcCtD
Irbesartan—Vomiting—Etoposide—urinary bladder cancer	0.000156	0.000548	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—urinary bladder cancer	0.000156	0.000547	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—urinary bladder cancer	0.000156	0.000547	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—urinary bladder cancer	0.000156	0.000547	CcSEcCtD
Irbesartan—Agitation—Epirubicin—urinary bladder cancer	0.000155	0.000544	CcSEcCtD
Irbesartan—Rash—Etoposide—urinary bladder cancer	0.000155	0.000543	CcSEcCtD
Irbesartan—Dermatitis—Etoposide—urinary bladder cancer	0.000155	0.000543	CcSEcCtD
Irbesartan—Headache—Etoposide—urinary bladder cancer	0.000154	0.00054	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—urinary bladder cancer	0.000154	0.000539	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—urinary bladder cancer	0.000154	0.000538	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—urinary bladder cancer	0.000154	0.000538	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—urinary bladder cancer	0.000154	0.000538	CcSEcCtD
Irbesartan—Tension—Doxorubicin—urinary bladder cancer	0.000153	0.000537	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000153	0.000536	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000152	0.000534	CcSEcCtD
Irbesartan—Malaise—Epirubicin—urinary bladder cancer	0.000152	0.000533	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—urinary bladder cancer	0.000152	0.000532	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—urinary bladder cancer	0.000152	0.000532	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—urinary bladder cancer	0.000152	0.000531	CcSEcCtD
Irbesartan—Syncope—Epirubicin—urinary bladder cancer	0.000151	0.00053	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—urinary bladder cancer	0.000151	0.00053	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00015	0.000526	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000148	0.00052	CcSEcCtD
Irbesartan—Cough—Epirubicin—urinary bladder cancer	0.000147	0.000516	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000147	0.000516	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—urinary bladder cancer	0.000147	0.000516	CcSEcCtD
Irbesartan—Infection—Methotrexate—urinary bladder cancer	0.000146	0.000513	CcSEcCtD
Irbesartan—Nausea—Etoposide—urinary bladder cancer	0.000146	0.000512	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—urinary bladder cancer	0.000146	0.000511	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000145	0.000508	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000144	0.000506	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—urinary bladder cancer	0.000144	0.000506	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000144	0.000505	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—urinary bladder cancer	0.000144	0.000504	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—urinary bladder cancer	0.000144	0.000504	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—urinary bladder cancer	0.000144	0.000504	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—urinary bladder cancer	0.000144	0.000503	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—urinary bladder cancer	0.000143	0.000502	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—urinary bladder cancer	0.000143	0.000501	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000143	0.0005	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000142	0.000499	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—urinary bladder cancer	0.000142	0.000498	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—urinary bladder cancer	0.000141	0.000494	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—urinary bladder cancer	0.000141	0.000493	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—urinary bladder cancer	0.00014	0.000492	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—urinary bladder cancer	0.00014	0.000492	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—urinary bladder cancer	0.00014	0.000491	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—urinary bladder cancer	0.00014	0.00049	CcSEcCtD
Irbesartan—Oedema—Epirubicin—urinary bladder cancer	0.000138	0.000483	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000138	0.000483	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—urinary bladder cancer	0.000138	0.000482	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000137	0.000481	CcSEcCtD
Irbesartan—Infection—Epirubicin—urinary bladder cancer	0.000137	0.00048	CcSEcCtD
Irbesartan—Cough—Doxorubicin—urinary bladder cancer	0.000136	0.000478	CcSEcCtD
Irbesartan—Shock—Epirubicin—urinary bladder cancer	0.000136	0.000475	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000135	0.000473	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000135	0.000473	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—urinary bladder cancer	0.000135	0.000473	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—urinary bladder cancer	0.000134	0.000471	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000134	0.00047	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—urinary bladder cancer	0.000134	0.000469	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000133	0.000467	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—urinary bladder cancer	0.000133	0.000466	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—urinary bladder cancer	0.000133	0.000466	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—urinary bladder cancer	0.000133	0.000466	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—urinary bladder cancer	0.000133	0.000464	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—urinary bladder cancer	0.000132	0.000463	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000132	0.000463	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—urinary bladder cancer	0.000131	0.00046	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—urinary bladder cancer	0.000131	0.00046	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—urinary bladder cancer	0.000131	0.00046	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—urinary bladder cancer	0.000131	0.000459	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—urinary bladder cancer	0.00013	0.000456	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—urinary bladder cancer	0.00013	0.000454	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—urinary bladder cancer	0.000129	0.000451	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—urinary bladder cancer	0.000128	0.000448	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000127	0.000447	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—urinary bladder cancer	0.000127	0.000447	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000127	0.000445	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—urinary bladder cancer	0.000127	0.000445	CcSEcCtD
Irbesartan—Infection—Doxorubicin—urinary bladder cancer	0.000127	0.000444	CcSEcCtD
Irbesartan—Pain—Methotrexate—urinary bladder cancer	0.000126	0.000441	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000126	0.00044	CcSEcCtD
Irbesartan—Shock—Doxorubicin—urinary bladder cancer	0.000125	0.000439	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000125	0.000438	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000125	0.000437	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—urinary bladder cancer	0.000124	0.000436	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—urinary bladder cancer	0.000124	0.000434	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—urinary bladder cancer	0.000124	0.000434	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000123	0.000432	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—urinary bladder cancer	0.000123	0.00043	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—urinary bladder cancer	0.000122	0.000429	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—urinary bladder cancer	0.000121	0.000426	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000121	0.000425	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—urinary bladder cancer	0.000121	0.000425	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00012	0.000422	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—urinary bladder cancer	0.00012	0.00042	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—urinary bladder cancer	0.000119	0.000417	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000119	0.000417	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—urinary bladder cancer	0.000119	0.000416	CcSEcCtD
Irbesartan—Constipation—Epirubicin—urinary bladder cancer	0.000118	0.000413	CcSEcCtD
Irbesartan—Pain—Epirubicin—urinary bladder cancer	0.000118	0.000413	CcSEcCtD
Irbesartan—Urticaria—Methotrexate—urinary bladder cancer	0.000117	0.00041	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—urinary bladder cancer	0.000116	0.000408	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000116	0.000408	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000116	0.000407	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000114	0.000401	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000114	0.000398	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000114	0.000398	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—urinary bladder cancer	0.000113	0.000397	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000113	0.000395	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000112	0.000393	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000111	0.000388	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00011	0.000386	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—urinary bladder cancer	0.00011	0.000385	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—urinary bladder cancer	0.000109	0.000384	CcSEcCtD
Irbesartan—Pain—Doxorubicin—urinary bladder cancer	0.000109	0.000382	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—urinary bladder cancer	0.000109	0.000382	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—urinary bladder cancer	0.000109	0.000382	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000109	0.000382	CcSEcCtD
Irbesartan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000108	0.00038	CcSEcCtD
Irbesartan—Asthenia—Methotrexate—urinary bladder cancer	0.000106	0.00037	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000105	0.000368	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000104	0.000365	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—urinary bladder cancer	0.000104	0.000365	CcSEcCtD
Irbesartan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000101	0.000356	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—urinary bladder cancer	0.000101	0.000355	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000101	0.000353	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000101	0.000353	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000101	0.000353	CcSEcCtD
Irbesartan—Asthenia—Epirubicin—urinary bladder cancer	9.88e-05	0.000346	CcSEcCtD
Irbesartan—Pruritus—Epirubicin—urinary bladder cancer	9.75e-05	0.000342	CcSEcCtD
Irbesartan—Dizziness—Methotrexate—urinary bladder cancer	9.73e-05	0.000341	CcSEcCtD
Irbesartan—Diarrhoea—Epirubicin—urinary bladder cancer	9.43e-05	0.00033	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.39e-05	0.000329	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—urinary bladder cancer	9.36e-05	0.000328	CcSEcCtD
Irbesartan—Rash—Methotrexate—urinary bladder cancer	9.28e-05	0.000325	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—urinary bladder cancer	9.27e-05	0.000325	CcSEcCtD
Irbesartan—Headache—Methotrexate—urinary bladder cancer	9.22e-05	0.000323	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—urinary bladder cancer	9.15e-05	0.000321	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—urinary bladder cancer	9.11e-05	0.000319	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—urinary bladder cancer	9.02e-05	0.000316	CcSEcCtD
Irbesartan—Vomiting—Epirubicin—urinary bladder cancer	8.76e-05	0.000307	CcSEcCtD
Irbesartan—Nausea—Methotrexate—urinary bladder cancer	8.74e-05	0.000306	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—urinary bladder cancer	8.72e-05	0.000306	CcSEcCtD
Irbesartan—Rash—Epirubicin—urinary bladder cancer	8.69e-05	0.000304	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—urinary bladder cancer	8.68e-05	0.000304	CcSEcCtD
Irbesartan—Headache—Epirubicin—urinary bladder cancer	8.63e-05	0.000302	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—urinary bladder cancer	8.43e-05	0.000295	CcSEcCtD
Irbesartan—Nausea—Epirubicin—urinary bladder cancer	8.18e-05	0.000287	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—urinary bladder cancer	8.1e-05	0.000284	CcSEcCtD
Irbesartan—Rash—Doxorubicin—urinary bladder cancer	8.04e-05	0.000282	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—urinary bladder cancer	8.03e-05	0.000281	CcSEcCtD
Irbesartan—Headache—Doxorubicin—urinary bladder cancer	7.98e-05	0.00028	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—urinary bladder cancer	7.57e-05	0.000265	CcSEcCtD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.87e-05	0.000145	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ENO2—urinary bladder cancer	3.83e-05	0.000143	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—HPGDS—urinary bladder cancer	3.83e-05	0.000143	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	3.82e-05	0.000143	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.81e-05	0.000143	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ESR1—urinary bladder cancer	3.8e-05	0.000142	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NCOR1—urinary bladder cancer	3.8e-05	0.000142	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	3.79e-05	0.000142	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTT1—urinary bladder cancer	3.72e-05	0.000139	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—MTHFR—urinary bladder cancer	3.72e-05	0.000139	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CDKN1A—urinary bladder cancer	3.71e-05	0.000139	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PTEN—urinary bladder cancer	3.7e-05	0.000139	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL2—urinary bladder cancer	3.7e-05	0.000138	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.66e-05	0.000137	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	3.61e-05	0.000135	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	3.59e-05	0.000135	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	3.58e-05	0.000134	CbGpPWpGaD
Irbesartan—JUN—Immune System—FGFR3—urinary bladder cancer	3.55e-05	0.000133	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EP300—urinary bladder cancer	3.53e-05	0.000132	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	3.52e-05	0.000132	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCL8—urinary bladder cancer	3.51e-05	0.000132	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	3.49e-05	0.000131	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.43e-05	0.000129	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—SRC—urinary bladder cancer	3.43e-05	0.000129	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TYMP—urinary bladder cancer	3.42e-05	0.000128	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL2—urinary bladder cancer	3.36e-05	0.000126	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TERT—urinary bladder cancer	3.35e-05	0.000125	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CREBBP—urinary bladder cancer	3.33e-05	0.000125	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF1—urinary bladder cancer	3.29e-05	0.000123	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.29e-05	0.000123	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—urinary bladder cancer	3.27e-05	0.000123	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.24e-05	0.000121	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.2e-05	0.00012	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—S100B—urinary bladder cancer	3.15e-05	0.000118	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NAT2—urinary bladder cancer	3.1e-05	0.000116	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—urinary bladder cancer	3.09e-05	0.000116	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NQO1—urinary bladder cancer	3.09e-05	0.000116	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FGFR3—urinary bladder cancer	3.07e-05	0.000115	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.06e-05	0.000114	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.03e-05	0.000114	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.03e-05	0.000114	CbGpPWpGaD
Irbesartan—JUN—Immune System—CREBBP—urinary bladder cancer	3.02e-05	0.000113	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RHOA—urinary bladder cancer	3.01e-05	0.000113	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PPARG—urinary bladder cancer	3.01e-05	0.000113	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—urinary bladder cancer	3.01e-05	0.000113	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDH1—urinary bladder cancer	3e-05	0.000112	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3e-05	0.000112	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ESR1—urinary bladder cancer	2.98e-05	0.000112	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.98e-05	0.000112	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CREBBP—urinary bladder cancer	2.89e-05	0.000108	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—urinary bladder cancer	2.84e-05	0.000106	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NCOR1—urinary bladder cancer	2.84e-05	0.000106	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMP—urinary bladder cancer	2.81e-05	0.000105	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.79e-05	0.000105	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB2—urinary bladder cancer	2.79e-05	0.000104	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.79e-05	0.000104	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.77e-05	0.000104	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.68e-05	0.0001	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—RRM2—urinary bladder cancer	2.67e-05	0.0001	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL8—urinary bladder cancer	2.65e-05	9.9e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—urinary bladder cancer	2.63e-05	9.84e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.61e-05	9.79e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CREBBP—urinary bladder cancer	2.61e-05	9.78e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF1—urinary bladder cancer	2.58e-05	9.66e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.58e-05	9.65e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—urinary bladder cancer	2.57e-05	9.61e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NAT2—urinary bladder cancer	2.54e-05	9.52e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB2—urinary bladder cancer	2.53e-05	9.47e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2—urinary bladder cancer	2.53e-05	9.46e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.52e-05	9.44e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TERT—urinary bladder cancer	2.5e-05	9.36e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.5e-05	9.35e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.49e-05	9.33e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	2.48e-05	9.27e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ENO2—urinary bladder cancer	2.48e-05	9.27e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—urinary bladder cancer	2.46e-05	9.23e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.46e-05	9.21e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—urinary bladder cancer	2.43e-05	9.08e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—urinary bladder cancer	2.42e-05	9.05e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	2.4e-05	8.99e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TYMS—urinary bladder cancer	2.4e-05	8.97e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—urinary bladder cancer	2.39e-05	8.96e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.39e-05	8.94e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDKN1A—urinary bladder cancer	2.38e-05	8.92e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.38e-05	8.92e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTEN—urinary bladder cancer	2.38e-05	8.9e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—urinary bladder cancer	2.37e-05	8.87e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NCOR1—urinary bladder cancer	2.37e-05	8.86e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTM1—urinary bladder cancer	2.37e-05	8.86e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RHOA—urinary bladder cancer	2.36e-05	8.85e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.36e-05	8.85e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.36e-05	8.83e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.3e-05	8.61e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FGFR3—urinary bladder cancer	2.29e-05	8.59e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—urinary bladder cancer	2.29e-05	8.58e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.29e-05	8.56e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EP300—urinary bladder cancer	2.27e-05	8.49e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GPX1—urinary bladder cancer	2.27e-05	8.49e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ESR1—urinary bladder cancer	2.23e-05	8.34e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ERCC2—urinary bladder cancer	2.23e-05	8.33e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SRC—urinary bladder cancer	2.21e-05	8.26e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.19e-05	8.22e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB2—urinary bladder cancer	2.19e-05	8.19e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.18e-05	8.14e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1A—urinary bladder cancer	2.16e-05	8.09e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTEN—urinary bladder cancer	2.16e-05	8.07e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.15e-05	8.06e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—MTHFR—urinary bladder cancer	2.09e-05	7.83e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—urinary bladder cancer	2.08e-05	7.77e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTEN—urinary bladder cancer	2.07e-05	7.74e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—urinary bladder cancer	2.06e-05	7.72e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EP300—urinary bladder cancer	2.06e-05	7.7e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.03e-05	7.61e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.03e-05	7.61e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.01e-05	7.54e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.01e-05	7.54e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2e-05	7.5e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—SRC—urinary bladder cancer	2e-05	7.49e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NQO1—urinary bladder cancer	2e-05	7.47e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—urinary bladder cancer	1.98e-05	7.43e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—urinary bladder cancer	1.98e-05	7.4e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.97e-05	7.38e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—EP300—urinary bladder cancer	1.97e-05	7.38e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.95e-05	7.32e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CREBBP—urinary bladder cancer	1.95e-05	7.31e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.94e-05	7.25e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—urinary bladder cancer	1.93e-05	7.24e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—urinary bladder cancer	1.93e-05	7.24e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1—urinary bladder cancer	1.93e-05	7.22e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.92e-05	7.2e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—urinary bladder cancer	1.88e-05	7.03e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.87e-05	7e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—urinary bladder cancer	1.87e-05	6.99e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.86e-05	6.96e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.84e-05	6.88e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—urinary bladder cancer	1.83e-05	6.84e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EP300—urinary bladder cancer	1.78e-05	6.66e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RHOA—urinary bladder cancer	1.77e-05	6.61e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—urinary bladder cancer	1.75e-05	6.56e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SRC—urinary bladder cancer	1.73e-05	6.48e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.72e-05	6.45e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.72e-05	6.45e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.71e-05	6.41e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.7e-05	6.35e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.69e-05	6.32e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.67e-05	6.25e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.66e-05	6.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.66e-05	6.22e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—urinary bladder cancer	1.66e-05	6.2e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.64e-05	6.16e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.64e-05	6.13e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—urinary bladder cancer	1.64e-05	6.12e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.63e-05	6.1e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.62e-05	6.08e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—urinary bladder cancer	1.62e-05	6.08e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.61e-05	6.03e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.58e-05	5.9e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—urinary bladder cancer	1.55e-05	5.81e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—urinary bladder cancer	1.55e-05	5.81e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—urinary bladder cancer	1.55e-05	5.81e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.55e-05	5.79e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.53e-05	5.73e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.53e-05	5.73e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—urinary bladder cancer	1.52e-05	5.68e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—urinary bladder cancer	1.48e-05	5.55e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.46e-05	5.48e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—urinary bladder cancer	1.44e-05	5.41e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.44e-05	5.38e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.43e-05	5.37e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—urinary bladder cancer	1.43e-05	5.37e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—urinary bladder cancer	1.41e-05	5.27e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—urinary bladder cancer	1.4e-05	5.25e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1A—urinary bladder cancer	1.4e-05	5.23e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—urinary bladder cancer	1.39e-05	5.22e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.39e-05	5.2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.37e-05	5.14e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.37e-05	5.12e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.35e-05	5.07e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.35e-05	5.06e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.35e-05	5.04e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.33e-05	5e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EP300—urinary bladder cancer	1.33e-05	4.98e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.33e-05	4.97e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.33e-05	4.97e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.31e-05	4.91e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SRC—urinary bladder cancer	1.29e-05	4.84e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.29e-05	4.83e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—urinary bladder cancer	1.27e-05	4.77e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.27e-05	4.76e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.26e-05	4.71e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.26e-05	4.7e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.26e-05	4.7e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.24e-05	4.66e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.24e-05	4.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—urinary bladder cancer	1.22e-05	4.56e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.2e-05	4.5e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.19e-05	4.46e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.18e-05	4.42e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.17e-05	4.4e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.17e-05	4.38e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.16e-05	4.36e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—urinary bladder cancer	1.16e-05	4.34e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.16e-05	4.33e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—urinary bladder cancer	1.13e-05	4.24e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.12e-05	4.19e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—EP300—urinary bladder cancer	1.11e-05	4.16e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.11e-05	4.15e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.1e-05	4.12e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.1e-05	4.1e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.08e-05	4.03e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.07e-05	4.01e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—urinary bladder cancer	1.07e-05	4.01e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.06e-05	3.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.06e-05	3.98e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.05e-05	3.94e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.02e-05	3.81e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1e-05	3.74e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—urinary bladder cancer	9.52e-06	3.56e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	9.4e-06	3.52e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—urinary bladder cancer	9.1e-06	3.41e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—urinary bladder cancer	9e-06	3.37e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.93e-06	3.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—urinary bladder cancer	8.92e-06	3.34e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	8.64e-06	3.24e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	8.62e-06	3.23e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	8.57e-06	3.21e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.3e-06	3.11e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.21e-06	3.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.21e-06	3.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.86e-06	2.94e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.72e-06	2.89e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—urinary bladder cancer	7.62e-06	2.85e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—urinary bladder cancer	7.52e-06	2.82e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	7.32e-06	2.74e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.25e-06	2.72e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—EP300—urinary bladder cancer	7.17e-06	2.68e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	7.08e-06	2.65e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	7.02e-06	2.63e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.17e-06	2.31e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—urinary bladder cancer	6.12e-06	2.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	6e-06	2.25e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.89e-06	2.2e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.88e-06	2.2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.84e-06	2.19e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.65e-06	2.12e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—urinary bladder cancer	5.23e-06	1.96e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—EP300—urinary bladder cancer	4.99e-06	1.87e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.63e-06	1.73e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.04e-06	1.51e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.85e-06	1.44e-05	CbGpPWpGaD
